Price
No data yet.
Social Signal Score
Analyst Ratings
26 analystsRevenue
$129.46M+442.32%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Chaim Indig
- Sector
- Healthcare
- Industry
- Medical - Healthcare Information Services
- Employees
- 1,789
- Beta
- 0.84
- Country
- US
- Piotroski score
- 4 / 9 (Middling)
- Altman Z-score
- 0.85
Financials
Revenue
$129.46M+442.3%Net Income
$1.92MEBITDA
$21.05M+2616.7%Free Cash Flow
$17.84MEPS (diluted)
$0.03Shares Outstanding (diluted)
62.46M+121.5%Operating Expenses
$68.67MCash & Debt
$72.94MReturn of Capital
$0.00Revenue by Segment (annual)
$480.59MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2026 | $480.59M | $2.31M | $0.04 |
| 2025 | $419.81M | $-58.53M | $-1.02 |
| 2024 | $356.30M | $-136.88M | $-2.51 |
| 2023 | $280.91M | $-176.15M | $-3.36 |
| 2022 | $213.23M | $-118.16M | $-2.37 |
| 2021 | $148.68M | $-27.29M | $-0.69 |
| 2020 | $124.78M | $-20.29M | $-1.00 |
| 2019 | $99.89M | $-15.06M | $-8.16 |
| 2018 | $79.83M | $-18.19M | $-11.82 |
Valuation
Project earnings forward and see what return today's price implies.
EPS was negative in at least one boundary year, so a compound growth rate can't be computed from it. Set your own assumption.
- EPS in 5 years
- $0.06
- Implied price
- $1.02
- Return from $10.94
- -37.8% a year
To earn 15.0% a year on these assumptions you'd need to buy at $0.51 — -95.4% below today's price.
How sensitive is that answer?
Annual return across nearby assumptions. If the result is only attractive in one corner, that is the finding.
| growth \ P/E | 12 | 15 | 18 | 21 | 24 |
|---|---|---|---|---|---|
| -2.0% | -47.9% | -45.6% | -43.5% | -41.8% | -40.2% |
| 3.0% | -45.3% | -42.8% | -40.7% | -38.8% | -37.1% |
| 8.0% | -42.6% | -40.0% | -37.8% | -35.8% | -34.1% |
| 13.0% | -40.0% | -37.2% | -34.9% | -32.9% | -31.0% |
| 18.0% | -37.3% | -34.4% | -32.0% | -29.9% | -28.0% |
This is arithmetic on assumptions you chose, not a forecast or a recommendation. It ignores dividends, buybacks, share issuance and debt, and it assumes a company still earning money in 5 years. Change any input and the answer changes a lot — that sensitivity is the honest result, not a flaw in the model.
Signal Score (90d)
50-65.52%Social Signal Score
Mentions (9)
- Newsbusinesswire.com·10d ago·Neutral
Phreesia's Michael Rasbury Named to Becker's 2026 List of Rising Stars: Healthcare Leaders Under 40 ALL-REMOTE COMPANY/WILMINGTON, Del.--(BUSINESS WIRE)--Phreesia's Michael Rasbury, VP of AccessOne Solutions, named to Becker's Hospital Review's 2026 Rising Stars: Healthcare Leaders Under 40 list.
View source ↗ - Newsbusinesswire.com·18d ago·Neutral
Phreesia Named to TIME's 2026 List of the World's Top HealthTech Companies ALL-REMOTE COMPANY/WILMINGTON, Del.--(BUSINESS WIRE)--Phreesia, a leader in patient intake, outreach and activation, has been named to TIME's list of the World's Top HealthTech Companies of 2026. This marks the second consecutive year Phreesia has been recognized on the list, which is developed in partnership with Statista to identify companies using technology to make healthcare more effective and accessible. The 2026 li
View source ↗ - Newsbusinesswire.com·34d ago·Neutral
Phreesia's ProviderConnect Audiences are Now Available in the DeepIntent Audience Marketplace ALL-REMOTE COMPANY/WILMINGTON, Del.--(BUSINESS WIRE)--Phreesia's ProviderConnect audiences are now available in the DeepIntent Audience Marketplace.
View source ↗ - Newsfool.com·40d ago·Neutral
Why Phreesia Stock Got Knocked Down Today This added to lingering negative sentiment following the company's latest earnings release. Investors didn't like the fact that it whiffed on earnings.
View source ↗ - Newsfool.com·45d ago·Neutral
Why Phreesia Stock Tumbled Today Although its net income rose sharply, analysts expected better. On a brighter note, the company slightly topped the consensus pundit estimate for revenue.
View source ↗ - Newsseekingalpha.com·46d ago·Positive
Phreesia, Inc. (PHR) Q2 2027 Earnings Call Transcript Phreesia, Inc. (PHR) Q2 2027 Earnings Call Transcript
View source ↗ - Newszacks.com·46d ago·Neutral
Phreesia (PHR) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates The headline numbers for Phreesia (PHR) give insight into how the company performed in the quarter ended July 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
View source ↗ - Newszacks.com·46d ago·Negative
Phreesia (PHR) Q2 Earnings and Revenues Lag Estimates Phreesia (PHR) came out with quarterly earnings of $0.03 per share, missing the Zacks Consensus Estimate of $0.11 per share. This compares to earnings of $0.01 per share a year ago.
View source ↗ - Newsmarketbeat.com·46d ago·Negative
Phreesia Q2 Earnings Call Highlights Phreesia NYSE: PHR reported second-quarter fiscal 2027 revenue growth and continued profitability expansion, while maintaining its full-year revenue and adjusted EBITDA outlook. The company said it generated positive operating and free cash flow for the ninth consecutive quarter and used its cash generation and available cash to reduce debt principal by more than $23 million.
View source ↗
Earnings
Mon, Dec 14(in 8 weeks)
Consensus estimate $0.13 per share
Typical surprise +44.1% (median, so one quarter with a near-zero estimate can't distort it)
- Wed, Sep 2$0.03 vs $0.09miss
- Wed, May 27$0.05 vs $0.02beat
- Mon, Mar 30$0.02 vs $0.07miss
- Mon, Dec 8$0.10 vs $-0.00beat
- Thu, Sep 4$0.01 vs $-0.07beat
- Wed, May 28$-0.07 vs $-0.13beat
Estimates and results for PHR via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by PHR officers and directors.
- Bought
- $28.8m
- Sold
- $1.2m
6 trades
25 trades
- Hoffman Allison Csold
- Hui Yvonnesold
- Egbuonu-davis Lisasold
- Hui Yvonnesold
- Egbuonu-davis Lisasold
- Hui Yvonnesold
- Hoffman Allison Csold
- Hui Yvonnesold
69 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
- Gilbert Cisneroshouse · CA31 · disclosed Sep 11, 2026 (16d later)Sell$1,001 - $15,000
- Gilbert Cisneroshouse · CA31 · disclosed Sep 11, 2026 (17d later)Sell$1,001 - $15,000
- Josh Gottheimerhouse · NJ05 · disclosed Apr 9, 2026 (35d later)Sell$1,001 - $15,000
- Gilbert Cisneroshouse · CA31 · disclosed Nov 18, 2025 (40d later)Buy$1,001 - $15,000
- Josh Gottheimerhouse · NJ05 · disclosed Nov 11, 2023 (26d later)Buy$1,001 - $15,000
- Josh Gottheimerhouse · NJ05 · disclosed Oct 15, 2023 (30d later)Sell$1,001 - $15,000
- Josh Gottheimerhouse · NJ05 · disclosed Jan 10, 2022 (26d later)Buy$1,001 - $15,000
- Gilbert Cisneroshouse · CA31 · disclosed Jan 11, 2021 (19d later)Sell$1,001 - $15,000
- Josh Gottheimerhouse · NJ05 · disclosed Jan 7, 2021 (17d later)Sell$1,001 - $15,000
- Gilbert Cisneroshouse · CA31 · disclosed Nov 5, 2020 (9d later)Buy$1,001 - $15,000
- Gilbert Cisneroshouse · CA31 · disclosed Oct 14, 2020 (15d later)Buy$1,001 - $15,000
- Gilbert Cisneroshouse · CA31 · disclosed May 13, 2020 (20d later)Buy$1,001 - $15,000
- Josh Gottheimerhouse · NJ05 · disclosed Mar 16, 2020 (42d later)Buy$1,001 - $15,000
- Gilbert Cisneroshouse · CA31 · disclosed Mar 10, 2020 (29d later)Buy$1,001 - $15,000
Self-reported filings, amounts as brackets. Via Senate/House disclosures.